← Russell 3000 cross-section

BBNX Beta Bionics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$875m
Revenue TTM
$119m
Net income TTM
$-73m
Free cash flow
$-61m
Composite score
Sector rank
#2095

Valuation

P / E
EV / EBITDA
EV / sales
5.8
FCF yield
-7.01%
Earnings yield vs 10-yr
-13.07pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-61.3%
EBITDA margin
-67.9%
ROE
-28.5%
ROIC
-109.4%
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.73m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the six months ended June 30, 2026 and 2025, PBP channel sales represented 37% and 21% of net sales, respectively. When considering the overall economics over the lifetime of each iLet, sales through the DME channel generally result in higher upfront cash flows from the large upfront payment and reimbursement for the iLet, but lead to lower cash flows over time as the user purchases the necessary single-use products. By contrast, sales through the PBP channel generally result in lower upfront cash flows from the small payment and reimbursement for the iLet, but lead to higher cash flows over time as the user purchases the necessary single-use products. …Beta Bionics, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →